Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...
Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...
Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down ...